Eloxx Pharmaceuticals, Inc. Income Statement
ELOX|4 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Eloxx Pharmaceuticals, Inc. reported $0 in revenue and $17M in net loss for FY2025. Revenue has grown at a 382.8% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|
| Revenue | $0 | $182.2K | $7.8K | $7.8K |
| SG&A Expense | $8.7M | $3.7M | $2.5M | $2.7M |
| R&D Expense | $8.6M | $3.3M | $2.1M | $2.6M |
| Operating Income | -$17.3M | -$9.1M | -$4.7M | -$5.4M |
| Interest Expense | - | - | $47.5K | $47.5K |
| Income Tax | $0 | $0 | - | - |
| Net Income | -$17.1M | -$9.2M | -$6.1M | -$5.1M |
| EPS (Basic) | -$6.63 | - | - | - |
| EPS (Diluted) | -$6.63 | -$2.53 | -$5.11 | -$7.81 |
| Shares Outstanding | 3.1M | 18.8M | 13.8M | 2.3M |
| Operating Margin | - | -5019.9% | -59476.9% | -69210.0% |
| Profit Margin | - | -5062.4% | -78303.4% | -64792.6% |